MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1148/radiol.2241011262

Медицинская библиотека · Radiology · 2002

Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Cammà Calogero, Schepis Filippo, Orlando Ambrogio, Albanese Maddalena, Shahied Lillian, Trevisani Franco, Andreone Pietro, Craxì Antonio, Cottone Mario

Сравнительное исследованиеСтатьяМетаанализОбзорПеревод в очереди

Аннотация

PURPOSE: To review the available evidence of chemoembolization for unresectable hepatocellular carcinoma (HCC).

MATERIALS AND

METHODS

Computerized bibliographic searches with MEDLINE and CANCERLIT databases from 1980 through 2000 were supplemented with manual searches, with the keywords "hepatocellular carcinoma," "liver cell carcinoma," "randomized controlled trial [RCT]," and "chemoembolization." Studies were included if patients with unresectable HCC were enrolled and if they were RCTs in which chemoembolization was compared with nonactive treatment (five RCTs) or if different transarterial modalities of therapy (13 RCTs) were compared. Data were extracted from each RCT according to the intention-to-treat method. Five of the RCTs with a nonactive treatment arm were combined by using the random-effects model, whereas all 18 RCTs were pooled from meta-regression analysis.

RESULTS

Chemoembolization significantly reduced the overall 2-year mortality rate (odds ratio, 0.54; 95% CI: 0.33, 0.89; P =.015) compared with nonactive treatment. Analysis of comparative RCTs helped to predict that overall mortality was significantly lower in patients treated with transarterial embolization (TAE) than in those treated with transarterial chemotherapy (odds ratio, 0.72; 95% CI: 0.53, 0.98; P =.039) and that there is no evidence that transarterial chemoembolization is more effective than TAE (odds ratio, 1.007; 95% CI: 0.79, 1.27; P =.95), which suggests that the addition of an anticancer drug did not improve the therapeutic benefit.

CONCLUSION

In patients with unresectable HCC, chemoembolization significantly improved the overall 2-year survival compared with nonactive treatment, but the magnitude of the benefit is relatively small.

Для цитирования: Cammà Calogero, Schepis Filippo, Orlando Ambrogio, Albanese Maddalena, Shahied Lillian, Trevisani Franco, Andreone Pietro, Craxì Antonio, Cottone Mario. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.. Radiology. 2002. DOI: 10.1148/radiol.2241011262.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.